Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 9;18(1):5.
doi: 10.1186/s12940-018-0445-3.

Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy

Rong Huang  1 , Qian Chen  1 , Lin Zhang  2 , Kai Luo  1   3 , Lin Chen  1 , Shasha Zhao  1 , Liping Feng  1   4 , Jun Zhang  5   6
Affiliations

Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and the risk of hypertensive disorders of pregnancy

Rong Huang et al. Environ Health. .

Abstract

Background: Perfluoroalkyl and polyfluoroalkyl substances (PFAS) have been reported to disrupt endocrine system and reproduction. However, epidemiological evidence on the association between PFAS and preeclampsia is inconsistent. We aimed to investigate the association between prenatal PFAS exposure and hypertensive disorders of pregnancy (HDP) in humans.

Methods: PFAS were measured by liquid chromatography system coupled with tandem mass spectrometry in 687 umbilical cord plasma samples collected between 2011 and 2012 in Shanghai, China. Information on HDP including gestational hypertension and preeclampsia was abstracted from medical records. Multiple logistic regression was used to examine the association of each PFAS with gestational hypertension, preeclampsia, and overall HDP in separate models. Elastic net regression with logit link was used to identify independent associations between exposures and outcomes. Logistic regression was used to obtain the unpenalized estimates of the selected PFAS components for the associations with outcomes, adjusting for age, education level, pre-pregnancy BMI, parity, and mutual adjustment of selected PFAS.

Results: The risk of gestational hypertension and preeclampsia was 3.3% and 2.8% in our subjects, respectively. Perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), perfluoroundecanoic acid (PFUA) were associated with preeclampsia based on elastic net penalty regression. In the fully adjusted statistical model, women with a higher level of standardized ln-transformed PFBS had an increased odds of preeclampsia [adjusted odds ratio (AOR): 1.81, 95% confidence interval (CI): 1.03-3.17], and overall HDP (AOR: 1.64, 95% CI: 1.09-2.47).

Conclusions: Prenatal exposure to PFBS was positively associated with the risk of preeclampsia and overall HDP.

Keywords: Cord blood; Gestational hypertension; PFAS; Preeclampsia.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The ethics approval was obtained from the Xinhua Hospital and International Peace Maternity and Infant Health affiliated to the Shanghai Jiao Tong University School of Medicine. This study was conducted in accordance with the principles of the Helsinki Declaration.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Correlation coefficients among the PFAS. **P < 0.01, *** < P < 0.001. Note: Non-straight lines mean that the relation between two PFAS may be non-linear
See this image and copyright information in PMC

References

    1. Ye C, Ruan Y, Zou L, Li G, Li C, Chen Y, Jia C, Megson IL, Wei J, Zhang W. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes. PLoS One. 2014;9(6):e100180. doi: 10.1371/journal.pone.0100180. - DOI - PMC - PubMed
    1. Magee L, Ornstein M, Von Dadelszen P. Management of hypertension in pregnancy. BMJ. 1999;318(7194):1332–1336. doi: 10.1136/bmj.318.7194.1332. - DOI - PMC - PubMed
    1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391–403. doi: 10.1016/j.bpobgyn.2011.01.006. - DOI - PubMed
    1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–137. doi: 10.1053/j.semperi.2009.02.010. - DOI - PubMed
    1. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066–1074. doi: 10.1016/S0140-6736(06)68397-9. - DOI - PubMed

Publication types